Headache is one of the most common complaints encountered in clinical practice. While most presentations represent benign primary headache disorders, a critical subset stems from life-threatening secondary etiologies ranging from central nervous system infections to intracranial vascular events. Establishing an accurate diagnosis through structured risk stratification, red flag screening, and targeted pharmacotherapy is vital to optimizing patient outcomes.
Clinical Practice Concept
Developing the appropriate diagnosis is critical. Patients with migraine without aura are frequently misdiagnosed as having tension-type or “sinus” headaches, leading to inadequate acute and preventive management.
1. Primary vs. Secondary Headaches
| Category | Pathophysiology & Definition | Common Clinical Examples |
|---|---|---|
| Primary Headache | Not associated with an underlying structural or systemic disease; arises from complex neurovascular mechanisms and genetic susceptibility. |
• Migraine (with or without aura) • Tension-type headache • Cluster headache |
| Secondary Headache | Directly caused by or symptomatically linked to another underlying condition; generally does not resolve until the root cause is treated. |
• Intracranial hemorrhage or neoplasm • CNS infection or systemic viremia • Elevated intracranial pressure (ICP) • Hypertensive emergency or cervical trauma |
Reassuring Acute Clinical Findings
In an acute clinical encounter, benign etiology is strongly supported by: a history of identical prior headaches, preserved cognitive function, a supple neck, a completely normal neurological examination, and symptom resolution during clinical observation.
2. Clinical Screening: The SNOOP Red Flags
The SNOOP mnemonic provides a structured framework to identify clinical warning signs that necessitate urgent neuroimaging or systemic workup.
| Flag | Clinical Features & Warning Signs | Possible Clinical Correlations |
|---|---|---|
| Systemic & Secondary | Fever, unexplained weight loss, underlying HIV, malignancy, pregnancy, anticoagulation, or severe HTN (>180/120 mm Hg). | Meningitis, encephalitis, intracranial metastasis, systemic inflammation, intracerebral hemorrhage. |
| Neurologic | Confusion, impaired alertness, nuchal rigidity, papilledema, focal cranial nerve deficits, or motor weakness. | CNS infection, mass lesion, acute ischemic/hemorrhagic stroke, vascular malformation, vasculitis. |
| Onset | Sudden, abrupt “thunderclap” onset (<1 minute to peak intensity); or onset triggered by cough, exertion, or Valsalva. | Subarachnoid hemorrhage (thunderclap), intracranial mass, increased ICP syndromes. |
| Older Age | New onset of headache in patients >50 years of age or very young children (<5 years). | Temporal (giant cell) arteritis, structural mass lesions, cerebrovascular disease. |
| Progression / Pattern | Progressive change in frequency/severity, postural variation (upright vs. recumbent), papilledema, or focal visual loss. | Medication overuse headache, subdural hematoma, intracranial hypertension/hypotension, posterior fossa lesions. |
3. Diagnostic Profiling of Primary Headaches
| Disorder | Pain Profile & Location | Duration & Demographics | Associated Features & Criteria |
|---|---|---|---|
| Tension-Type | Pressing, tight, band-like quality. Mild-to-moderate intensity; typically bilateral. | 30 min to 7 days (usually 1–24 h). Female:Male ratio = 5:4. | No more than one: mild nausea, photophobia, or phonophobia (never both photophobia and phonophobia). No vomiting. |
| Migraine (without aura) | Pulsating/throbbing, moderate-to-severe intensity, typically unilateral. Exacerbated by routine physical activity. | 4 to 72 hours (~80% of all migraines). Female:Male ratio = 2:1. | Nausea, vomiting, photophobia, and phonophobia. Prodromal agitation or cravings may occur. Strong family history (70–90%). |
| Migraine (with aura) | Identical head pain parameters to migraine without aura. | Aura develops over 5–20 min and lasts <60 min (~20% of cases). | Fully reversible neurological aura (visual scotomas, sensory, speech/language). Pain severity is identical to non-aura events. |
| Cluster Headache | Excruciating, knife-like/orbital/temporal pain (“suicide headache”), strictly unilateral. | 15 to 180 min; occurs 1–8 times daily in clusters lasting weeks. Male predominance (1:3 to 1:8). | Ipsilateral autonomic signs: lacrimation, conjunctival injection, rhinorrhea, miosis/ptosis, facial sweating. “Alarm clock” nocturnal onset. |
Common Diagnostic Pitfalls
Migraines accompanied by prominent neck pain are frequently misdiagnosed as tension-type headaches, while those presenting with facial pressure and nasal congestion are often misclassified as “sinus” headaches, leading to unnecessary antibiotic courses and delayed effective care.
4. Neuroimaging Selection Criteria
Routine neuroimaging yields minimal diagnostic value in patients with stable, nonacute primary headaches and a normal physical and neurological examination. Imaging is specifically reserved for presentations exhibiting red flags.
| Modality | Clinical Advantages | Limitations & Disadvantages |
|---|---|---|
| Head CT (Non-contrast) | Rapid acquisition (5–10 min); highly sensitive for acute subarachnoid hemorrhage, bony trauma, and mass effect; widely available and lower cost. | Ionizing radiation exposure; potential contrast reactivity if contrast used; inferior resolution for subtle soft tissue, brainstem, or posterior fossa pathology. |
| Brain MRI | No ionizing radiation; superior multiplanar soft-tissue detail; highly sensitive for small ischemia, demyelination, venous thrombosis, and tumor margins. | Long acquisition time (~45 min); higher cost; contraindicated with certain metallic implants or severe claustrophobia. |
Special Diagnostic Considerations
- Giant Cell (Temporal) Arteritis: In patients >50 years presenting with a new localized headache, evaluate erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) to prevent ischemic vision loss.
- Intracranial Pressure Dynamics: Headaches from elevated ICP are typically severe upon awakening (due to nocturnal recumbent venous accumulation) and improve after assuming an upright position during the day.
5. Environmental, Dietary, and Rebound Triggers
Identifying and modifying individual triggers forms the cornerstone of non-pharmacological primary headache management.
- Lifestyle & Environmental Factors: Hormonal shifts (menses, ovulation, oral contraceptives), strenuous exertion, jet lag, irregular sleep schedules, fasting/skipped meals, high altitude, bright flickering lights, environmental loud noises, tobacco smoke, and acute stress or post-stress “letdown.”
- Dietary Factors: Caffeinated or alcoholic beverages, dark chocolate, aged/ripened cheeses (cheddar, Brie), cured or processed meats containing nitrates, pickled/fermented foods, sour cream, monosodium glutamate (MSG), freshly baked yeast products, nuts, figs, citrus fruits, and artificial sweeteners (aspartame).
Medication-Overuse Headache (Rebound Risk)
Frequent, long-term use of acute analgesics causes refractory medication-overuse headache. Combination OTC analgesics containing caffeine/aspirin/acetaminophen and prescription agents with butalbital or opioids carry high rebound potential. Simple NSAIDs (ibuprofen, naproxen) carry a comparatively lower risk when limited to <10–12 days per month.
6. Acute & Abortive Pharmacotherapy
| Drug Class | Representative Agents | Mechanism & Clinical Utility | Safety & Contraindications |
|---|---|---|---|
| Triptans | Sumatriptan, Rizatriptan, Zolmitriptan, Naratriptan, Frovatriptan | Selective 5-HT1B/1D agonists. First-line for moderate-to-severe acute migraine and cluster attacks. | Contraindicated in CAD, Prinzmetal angina, stroke history, uncontrolled HTN, and pregnancy. Serotonin syndrome risk with SSRIs. |
| Ditans | Lasmiditan | Selective 5-HT1F agonist. Aborts migraine pain without inducing vasoconstriction. | Schedule V agent. Causes significant CNS depression; driving restricted for at least 8 hours post-dose. |
| Oral Gepants | Rimegepant, Ubrogepant | Small-molecule CGRP receptor antagonists. Effective acute therapy without vasoconstrictive effects. | Avoid co-administration with strong CYP3A4 inhibitors. High relative treatment cost. |
| NSAIDs & Analgesics | Ibuprofen, Naproxen, Aspirin, Acetaminophen | Cyclooxygenase inhibitors. First-line for tension-type and mild-to-moderate migraine episodes. | Gastric mucosal irritation, bleeding risk, renal impairment with chronic use. |
| Ergot Derivatives | Dihydroergotamine (DHE), Ergotamine tartrate | Non-selective 5-HT1 agonists. Used for severe or intractable status migrainosus. Ineffective for tension headache. | Contraindicated in CAD, peripheral vascular disease, renal disease, and pregnancy due to potent vasoconstriction. |
| Antiemetics / Neuroleptics | Prochlorperazine, Promethazine, Metoclopramide, Ondansetron | D2 or 5-HT3 antagonists. Treat associated nausea and enhance gastric motility (metoclopramide). | Extrapyramidal symptoms (EPS) and QT prolongation with dopamine antagonists; limit use to 2–3 days per week. |
| Cluster Abortives | 100% High-Flow O2 (12–15 L/min), Subcutaneous Sumatriptan, Intranasal Lidocaine | Rapid delivery abortives targeted to disrupt fast-crescendo, short-duration cluster attacks. | Oral treatments are generally ineffective due to the rapid peak of cluster pain. |
Administration & Rescue Strategies
- Route Selection: Oral formulations take 30–60 minutes to act and are suitable for gradual-onset pain. Non-oral routes (nasal sprays, subcutaneous injections) act within 15–30 minutes and are essential for severe nausea, vomiting, or rapidly escalating pain.
- Intractable Pain & Rescue: Short courses of systemic corticosteroids (e.g., prednisone 20 mg QID for 2 days) can break status migrainosus or cluster cycles. Opioid analgesics should be strictly avoided due to addiction potential and high rebound rates.
7. Prophylactic (Preventive) Strategies
Preventive therapy should be initiated when headaches significantly impair quality of life, occur >4 days per month, or fail to respond to acute abortives. The therapeutic benchmark is a ≥50% reduction in monthly headache frequency within 1–2 months of continuous use.
| Drug Class | First-Line Clinical Agents | Clinical Nuances & Key Considerations |
|---|---|---|
| Beta-Blockers | Propranolol, Metoprolol, Atenolol, Nadolol | Strongest evidence base for migraine prophylaxis. Avoid in severe asthma, symptomatic bradycardia, or heart block. |
| Antiepileptic Drugs (AEDs) | Topiramate, Divalproex Sodium, Sodium Valproate | Highly effective for frequent migraine. High teratogenic risk—requires reliable contraception counseling in reproductive-age females. (Lamotrigine is ineffective for migraine prophylaxis). |
| Antidepressants | Amitriptyline, Nortriptyline (TCAs); Venlafaxine (SNRI) | TCAs are first-line for tension-type headache prevention and effective in migraine. Beneficial in co-morbid depression, anxiety, or insomnia. |
| CGRP Monoclonal Antibodies | Erenumab, Fremanezumab, Galcanezumab | Injectable targeted biologics blocking CGRP ligands or receptors. Rapid onset (1–2 weeks), excellent tolerability profile, higher cost. |
| Cluster Prophylaxis | Verapamil, Lithium, Topiramate | Verapamil (calcium channel blocker) is the primary first-line preventive agent used to shorten active cluster cycles. |
| Nutraceuticals & Supplements | Riboflavin (B2), Magnesium, CoQ10, Feverfew, Butterbur | Butterbur and high-dose magnesium show favorable preventive benefit. Nutraceutical safety during pregnancy and lactation is unestablished. |
Clinical Practice Pearls
- Screen Systematically with SNOOP: Rule out secondary life-threatening headaches before confirming a primary disorder diagnosis.
- Re-Evaluate “Sinus” and “Tension” Labels: A recurrent, disabling headache accompanied by photophobia, nausea, or clear nasal discharge is almost always a migraine.
- Audit Monthly Analgesic Days: Monitor acute medication intake strictly to prevent the transformation of episodic headache into chronic medication-overuse headache.
